{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+acetate&page=2",
    "query": {
      "intervention": "Methylprednisolone acetate",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 582,
    "total_pages": 59,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+acetate&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+acetate&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T14:05:52.190Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01998633",
      "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "Chronic Active Epstein-Barr Virus Infection",
        "Chronic Granulomatous Disease",
        "HIGM-1",
        "Leukocyte Adhesion Deficiency",
        "IPEX"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Months to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998633"
    },
    {
      "nct_id": "NCT02495077",
      "title": "Effects of Inhibiting Early Inflammation in Kidney Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Loratadine",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2015-11-02",
      "completion_date": "2021-07-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02495077"
    },
    {
      "nct_id": "NCT02229136",
      "title": "Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stomatitis",
        "Oral Mucositis",
        "Neoplasm of the Breast",
        "Malignant Tumor of Breast"
      ],
      "interventions": [
        {
          "name": "Miracle Mouthwash Plus Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Oncology Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 104,
      "start_date": "2014-09-04",
      "completion_date": "2022-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-01",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "US, Texas",
      "locations": [
        {
          "city": "US",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229136"
    },
    {
      "nct_id": "NCT00698724",
      "title": "Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "Xibrom, and Optive",
          "type": "DRUG"
        },
        {
          "name": "Xibrom and Pred Forte",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-10",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "Tarpon Springs, Florida",
      "locations": [
        {
          "city": "Tarpon Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698724"
    },
    {
      "nct_id": "NCT04200651",
      "title": "Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dexamethasone Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1% Oph Susp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye Surgery Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2020-01-13",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04200651"
    },
    {
      "nct_id": "NCT05800366",
      "title": "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jennifer Crombie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2023-04-06",
      "completion_date": "2029-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Boston, Massachusetts",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05800366"
    },
    {
      "nct_id": "NCT01448213",
      "title": "Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fuchs' Dystrophy",
        "Bullous Keratopathy"
      ],
      "interventions": [
        {
          "name": "Prednisolone acetate",
          "type": "DRUG"
        },
        {
          "name": "Fluorometholone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Price Vision Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2011-10",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2014-09-03",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448213"
    },
    {
      "nct_id": "NCT00381810",
      "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2006-06-22",
      "completion_date": "2012-02-29",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 11,
      "location_summary": "Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more",
      "locations": [
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381810"
    },
    {
      "nct_id": "NCT00006054",
      "title": "Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immunologic Deficiency Syndromes",
        "Chediak-Higashi Syndrome",
        "Common Variable Immunodeficiency",
        "Graft Versus Host Disease",
        "X-Linked Lymphoproliferative Syndrome",
        "Familial Erythrophagocytic Lymphohistiocytosis",
        "Hemophagocytic Lymphohistiocytosis",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "X-linked Hyper IgM Syndrome",
        "Severe Combined Immunodeficiency",
        "Leukocyte Adhesion Deficiency Syndrome",
        "Virus-Associated Hemophagocytic Syndrome"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fairview University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "Up to 35 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006054"
    },
    {
      "nct_id": "NCT02197273",
      "title": "Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis, Knee",
        "Osteoarthritis, Hip",
        "Osteoarthritis, Shoulder"
      ],
      "interventions": [
        {
          "name": "Liposomal bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Standard of care analgesia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OhioHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2014-07",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2016-10-21",
      "last_synced_at": "2026-10-02T14:05:52.190Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197273"
    }
  ]
}